- Title
- MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis
- Creators
- Terrence Bradley - Sylvester Comprehensive Cancer CenterAndrew Kuykendall - Moffitt Cancer CenterRami S. Komrokji - Moffitt Cancer CenterTymara Berry - 4Geron Corporation, Parsippany, NJSouria Dougherty - 4Geron Corporation, Parsippany, NJLaurie Sherman - 4Geron Corporation, Parsippany, NJLixian Peng - 4Geron Corporation, Parsippany, NJFei Huang - 4Geron Corporation, Parsippany, NJYing Wan - 4Geron Corporation, Parsippany, NJFaye Feller - 4Geron Corporation, Parsippany, NJJohn Mascarenhas - Icahn School of Medicine at Mount Sinai
- Publication Details
- Blood, Vol.140(Supplement 1), pp.3941-3942
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031786478902976
Journal article
MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis
Blood, Vol.140(Supplement 1), pp.3941-3942
2022-11-15
Metrics
1 Record Views
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites